Scleroderma and Lupus Health Study Claims No Environmental Link To Disease PDF Print E-mail
Friday, 08 January 2010 22:09
taken from http://www.flickr.com/photos/h_de_c/3291978657/ via creative commonsThe Massachusetts Department of Public Health (DPH) has released the results of an investigation into the occurrence of scleroderma and lupus, two rare chronic diseases, in South Boston. The investigation found that the prevalence of scleroderma was indeed statistically significantly higher than expected among Caucasian females. No specific associations with environmental exposures were identified.

The study did confirm that a previous diagnosis of rheumatoid arthritis was associated with scleroderma and lupus among current and former South Boston residents. Further, the study also found that a family history of specific rheumatic diseases was significantly associated with a diagnosis of scleroderma and lupus.

The Department of Public Health's study was initiated in 1998, as a result of concerns raised by the South Boston community and then-State Senator Stephen F. Lynch, who now represents Massachusetts' 9th congressional district. At that time, the community expressed concerns about a perceived increase in the number of women who had grown up in South Boston and were later diagnosed with scleroderma. Community members also expressed concern about possible environmental exposure.

"The release of this study represents more than ten years of collaboration between the Massachusetts Department of Public Health and the South Boston community to address concerns of the prevalence of scleroderma and lupus," Congressman Stephen F. Lynch said. "I am pleased to see that this study has been completed and the results will guide future research and help those living with these chronic diseases."

DPH Commissioner John Auerbach added, "These types of studies are important and enhance our collaboration with community partners to improve public health."

DPH responded to the communities’ concerns by collaborating with clinical researchers and epidemiologists at Boston Medical Center, Tufts Medical Center and the South Boston Community Health Center to conduct a retrospective case-control study to investigate the occurrences of both diseases and to identify possible contributing factors (environmental and non-environmental) among individuals with scleroderma and lupus. In addition, DPH established a South Boston Community Advisory Committee to facilitate community outreach and ongoing communication.

Study participants were interviewed about their residential, occupational, medical, family and reproductive histories, as well as hobbies and recreational activities in the area. The study also investigated possible historical exposures to a number of sources of environmental pollution, as well as spatial and temporal (time) patterns among current and former residents with these diseases.

Source: Office of Health and Human Services (EOHHS)

If you're logged in, you can download a copy of the report, presentation, and questions and answers below.

 
More articles :

» Vitamin D More Important Now, Than Before

Vitamin D is something of a wonder drug, but bad things can happen if your body isn’t getting enough. Those who get adequate levels of vitamin D are better able to ward off everything from cancer to heart disease to autoimmune disease.But here’s...

» What is Chelation Therapy?

Chelation (pronounced key-LAY-shun) therapy is a chemical process in which a synthetic solution-EDTA (ethylenediaminetetraacetic acid) is injected into the bloodstream to remove heavy metals and/or minerals from the body. Chelation means "to grab"...

» Scleroderma and the Kidney

John F Donohoe Principle DiscussantPublished: Kidney International (1992) 41, 462–477; doi:10.1038/ki.1992.65Source: http://www.nature.com/ki/journal/v41/n2/abs/ki199265a.html

» Actelion Fibrosis Drug Doesn't Meet Key Endpoint

Actelion Ltd today announced the initial results of BUILD-3, a clinical study evaluating the safety and efficacy of Bosentan in patients suffering from idiopathic pulmonary fibrosis. While there was a consistent trend in favour of Bosentan, the...

» New Formulation of PAH Medication Is Now Available

Epoprostenol for Injection, an improved formulation of epoprostenol that is stable at room temperature, is now commercially available, according to the drug's maker, Actelion Pharmaceuticals US, Inc., of South San Francisco, Calif.The product is...

» Bring Christmas Cheer To Someone In Hospital

Disease and trauma do not take a holiday. Many of us have loved ones in the hospital for all kinds of reasons. We want to do what we can for them, our brothers, sisters, friends, parents, children, who find themselves in strange surroundings during...